Talk to Explore the Importance of Trial Design for Interventional Studies

Ravi I. Thadhani


Adaptive Trial Design for Acute Kidney Injury (AKI) Interventional Studies” is the title of the Robert W. Schrier, MD, Endowed Lectureship on Thursday, Nov. 5.

The speaker, Ravi I. Thadhani, MD, MPH, is chief of the renal unit and director of clinical research in nephrology at Massachusetts General Hospital in Boston and a professor of medicine at Harvard Medical School.

Dr. Thadhani has two major areas of research interest: medical complications of pregnancy and dialysis mortality. His main focus in the study of kidney disease is the cardiovascular and infectious consequences of defective vitamin D signaling in individuals with renal failure. His team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure. He has collaborated with basic scientists to move these hypotheses forward, and is currently performing randomized trials to formally test the hypotheses in humans.

His research has led to the publication of more than 150 peer-reviewed articles, eight book chapters, and many review articles and invited commentaries. Dr. Thadhani has also mentored several fellows and junior faculty members, who have a strong track record of publications and grant support and earned many faculty appointments at leading institutions around the country.

He has served ASN in a variety of capacities, including as a member of the clinical science committee and the annual meeting program committee as well as co-chair of the late-breaking clinical trials committee. For the National Kidney Foundation, he has chaired the clinical research committee and served on the annual meeting planning committee.

He has been on the editorial boards of the Journal of the American Society of Nephrology, Kidney International, and Nephrology Dialysis Transplantation. He was associate editor of the American Journal of Kidney Diseases and has been a guest editor of the Journal of the American Society of Nephrology.

Dr. Thadhani received his medical degree from the University of Pennsylvania and his MPH from the Harvard School of Public Health.

ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Robert W. Schrier, MD, Endowed Lectureship.